echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Recombinant new coronavirus fusion protein vaccine, a subsidiary of Joincare Pharmaceuticals, has been approved for clinical use

    Recombinant new coronavirus fusion protein vaccine, a subsidiary of Joincare Pharmaceuticals, has been approved for clinical use

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 24, Joincare Pharmaceuticals issued an announcement stating that the clinical trial application of the "recombinant new coronavirus fusion protein vaccine" developed by its holding subsidiary Livzumab was approved by the State Food and Drug Administration.


    Recombinant new coronavirus fusion protein vaccine (hereinafter referred to as: V-01) has been developed since July 2020.


    According to LSHTM tracker information, as of March 22, 2021, a total of 86 new crown vaccine products worldwide are in clinical trials, of which 13 products have been approved for marketing or emergency use authorization.


    In the clinical trial stage, 13 products have been approved for marketing or emergency use authorization.
    China has won strips of ratification listed a total of 4 models, 1 for emergency use approved models, 17 models in clinical trials (recombinant protein 4, paragraph technical route).
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.